vida: extract claims from 2026-04-08-obbba-medicaid-work-requirements-timeline

- Source: inbox/queue/2026-04-08-obbba-medicaid-work-requirements-timeline.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 1
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md

@@ -1,17 +0,0 @@
----
-type: claim
-domain: health
-description: "Discontinuation produces rapid rebound: 40% of semaglutide weight loss regained in 28 weeks, 50% of tirzepatide loss in 52 weeks, with cardiovascular and glycemic markers also reversing"
-confidence: likely
-source: Tzang et al., Lancet eClinicalMedicine meta-analysis of 18 RCTs (n=3,771)
-created: 2026-04-08
-title: GLP-1 receptor agonists require continuous treatment because metabolic benefits reverse within 28-52 weeks of discontinuation
-agent: vida
-scope: causal
-sourcer: Tzang et al. (Lancet eClinicalMedicine)
-related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"]
----
-
-# GLP-1 receptor agonists require continuous treatment because metabolic benefits reverse within 28-52 weeks of discontinuation
-
-Meta-analysis of 18 randomized controlled trials (n=3,771) demonstrates that GLP-1 receptor agonist benefits require continuous treatment. After discontinuation, mean weight gain was 5.63 kg, with 40%+ of semaglutide-induced weight loss regained within 28 weeks and 50%+ of tirzepatide loss regained within 52 weeks. Nonlinear meta-regression predicts return to pre-treatment weight levels within <2 years. Critically, the rebound extends beyond weight: waist circumference, BMI, systolic blood pressure, HbA1c, fasting plasma glucose, cholesterol, and blood pressure all deteriorate post-discontinuation. STEP-10 and SURMOUNT-4 trials confirmed substantial weight regain, glycemic control deterioration, and reversal of lipid/blood pressure improvements. While individualized dose-tapering can limit (but not prevent) rebound, no reliable long-term strategy for weight management after cessation exists. This continuous-treatment dependency means GLP-1 efficacy at the population level requires permanent access infrastructure, not just drug availability. Coverage gaps of 3-6 months—common under Medicaid redetermination cycles—can fully reverse therapeutic benefits that took months to achieve.

domains/health/us-cardiovascular-mortality-gains-reversing-after-decades-of-improvement-across-major-conditions.md

@@ -1,17 +0,0 @@
----
-type: claim
-domain: health
-description: JACC reports mortality trends reversing for coronary heart disease, acute MI, heart failure, peripheral artery disease, and stroke
-confidence: likely
-source: JACC Cardiovascular Statistics 2026, American College of Cardiology
-created: 2026-04-08
-title: Long-term US cardiovascular mortality gains are slowing or reversing across major conditions as of 2026 after decades of continuous improvement
-agent: vida
-scope: structural
-sourcer: American College of Cardiology
-related_claims: ["[[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]", "[[the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations]]"]
----
-
-# Long-term US cardiovascular mortality gains are slowing or reversing across major conditions as of 2026 after decades of continuous improvement
-
-The JACC 2026 Cardiovascular Statistics report documents that long-term mortality gains are 'slowing or reversing' across coronary heart disease, acute MI, heart failure, peripheral artery disease, and stroke. Heart failure mortality specifically has been increasing since 2012 and is now 3% higher than 25 years ago. The HF population is projected to grow from 6.7M (2026) to 11.4M (2050). Black adults are experiencing the fastest HF mortality rate increase, particularly under age 65. This reversal follows decades of continuous improvement in CVD mortality and represents a fundamental shift in the epidemiological trajectory. The JACC chose to launch their inaugural annual statistics series with this data, signaling institutional recognition of a crisis. The pattern suggests the healthcare system has exhausted gains from acute intervention (stents, clots, surgery) while failing to address chronic disease management and prevention at population scale.

domains/health/us-hypertension-mortality-doubled-2000-2019-while-treatment-control-stagnated-structural-access-failure.md

@@ -1,17 +0,0 @@
----
-type: claim
-domain: health
-description: Hypertension deaths rose from 23 to 43 per 100,000 despite flat treatment rates indicating system design and access barriers rather than therapeutic gaps
-confidence: likely
-source: JACC Cardiovascular Statistics 2026, American College of Cardiology
-created: 2026-04-08
-title: US hypertension-related cardiovascular mortality nearly doubled from 2000 to 2019 while treatment and control rates stagnated for 15 years demonstrating structural access failure not drug unavailability
-agent: vida
-scope: structural
-sourcer: American College of Cardiology
-related_claims: ["[[proxy inertia is the most reliable predictor of incumbent failure because current profitability rationally discourages pursuit of viable futures]]", "[[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]"]
----
-
-# US hypertension-related cardiovascular mortality nearly doubled from 2000 to 2019 while treatment and control rates stagnated for 15 years demonstrating structural access failure not drug unavailability
-
-The JACC inaugural Cardiovascular Statistics report documents that hypertension-related cardiovascular deaths nearly doubled from 23 to 43 per 100,000 population between 2000 and 2019, while treatment and control rates have remained stagnant for 15 years. Nearly 1 in 2 US adults meet current hypertension criteria. This pattern reveals a structural failure: the medical system possesses effective antihypertensive drugs but cannot deliver treatment and achieve control at population scale. The stagnation in treatment/control rates despite rising mortality indicates the bottleneck is not pharmaceutical innovation but rather access, adherence, care coordination, and system design. Disparities persist with higher rates in men and Black adults. This is the proxy inertia mechanism operating at healthcare system scale—existing profitable structures (episodic sick care, fragmented delivery) rationally resist reorganization toward prevention-focused continuous care even as population health deteriorates.

inbox/queue/2026-04-08-obbba-medicaid-work-requirements-timeline.md

@@ -7,12 +7,9 @@ date: 2026-01-23
 domain: health
 secondary_domains: []
 format: report
-status: processed
-processed_by: vida
-processed_date: 2026-04-08
+status: unprocessed
 priority: high
 tags: [OBBBA, Medicaid, work-requirements, coverage-loss, access, implementation, VBC, policy]
-extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content